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Cell-mediated immunityCMV infection is characterized by high of frequencies of CD27−CD28− T cells. Here we demonstrate that
CMV-speciﬁc CD4+CD27−CD28− cells are regulatory T cells (TR). CD4+CD27−CD28− cells sorted from CMV-
stimulated PBMC of CMV-seropositive donors inhibited de novo CMV-speciﬁc proliferation of autologous
PBMC in a dose-dependent fashion. Compared with the entire CMV-stimulated CD4+ T-cell population,
higher proportions of CD4+CD27−CD28− TR expressed FoxP3, TGFβ, granzyme B, perforin, GITR and PD-1,
lower proportions expressed CD127 and PD1-L and similar proportions expressed CD25, CTLA4, Fas-L and
GITR-L. CMV-CD4+CD27−CD28− TR expanded in response to IL-2, but not to CMV antigenic restimulation.
The anti-proliferative effect of CMV-CD4+CD27−CD28− TR signiﬁcantly decreased after granzyme B or TGFβ
inhibition. The CMV-CD4+CD27−CD28− TR of HIV-infected and uninfected donors had similar phenotypes
and anti-proliferative potency, but HIV-infected individuals had higher proportions of CMV-CD4+CD27−
CD28− TR. The CMV-CD4+CD27−CD28− TR may contribute to the downregulation of CMV-speciﬁc and
nonspeciﬁc immune responses of CMV-infected individuals.
© 2009 Elsevier Inc. All rights reserved.Introduction
The role of natural regulatory T cells (TR) in the modulation of
immune responses against self antigens has been well established
(Jonuleit and Schmitt, 2003; Rubtsov and Rudensky, 2007). Natural TR
were also shown to attenuate immune responses against grafted non-
self (Adeegbe et al., 2006; Joffre et al., 2008; Sandner et al., 2005) and
microbial antigens (Aandahl et al., 2004; Chougnet and Shearer, 2007;
Estes et al., 2006;Haribhai et al., 2007; Kinter et al., 2007; Li et al., 2008;
Nilsson et al., 2006; Smyk-Pearson et al., 2008; Sufﬁa et al., 2006) and
to hinder clearance of neoplastic proliferation (Beyer et al., 2006;
Broderick and Bankert, 2006; Chemnitz et al., 2007; Curiel et al., 2003;
Filaci et al., 2007). Natural TR with CD4+CD25+FoxP3+ phenotype are
generated in the thymus, but CD4+CD25− cells can also acquire TR
phenotypes and function in the periphery (Curotto de Lafaille et al.,
2004; Kretschmer et al., 2005; Stephens et al., 2007; Vukmanovic-
Stejic et al., 2006; Walker et al., 2005). Although there is growing
evidence that adaptive TR may arise as a consequence of antigenic
stimulation and speciﬁcally target the responses against neoplastic
cells or microbial pathogens, the characterization of this process is
incomplete (Vlad et al., 2005).
TR are functionally characterized by their ability to inhibit
proliferation of autologous T lymphocytes in response to antigenic
stimulation. Phenotypically, the expression of the forkhead transcrip-
tion factor FoxP3 has been used as a uniquemarker of TR (Jonuleit and8604, Aurora CO 80045, USA.
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ll rights reserved.Schmitt, 2003; Stephens et al., 2007). FoxP3 is not only a marker, but
plays an important role in the differentiation, function and survival of
CD4+ TR (Allan et al., 2005; Fontenot and Rudensky, 2005; Marson et
al., 2007; Tone et al., 2008; Zheng et al., 2007; Zheng and Rudensky,
2007). FoxP3 regulates the expression of several hundreds cellular
genes either directly or indirectly by modulating expression of other
transcription factors. Both mice and humans with genetic defects in
the FoxP3 gene develop aggressive auto-immune disorders that can
be controlled in mice by adoptive transfer of CD4+CD25+ TR from
healthy animals. Other cell surface markers that are commonly used
to identify TR are CTLA4, GITR/ GITR-L, GPR83, PD-1/PD1-L and CD127
(Hansen et al., 2006; Liu et al., 2006; Sandner et al., 2005; Seddiki et
al., 2006; Sharpe et al., 2007; Shevach and Stephens, 2006; Weihong
et al., 2006). The exact mechanism used by TR to downmodulate
immune responses has not been completely elucidated (von Boeh-
mer, 2005). To date, there is strong evidence that TGFβ and IL-10
mediate some TR activities (Jonuleit and Schmitt, 2003; Mekala et al.,
2005; Thomas and Massague, 2005). In addition, TGFβ also enhances
the expression of FoxP3 and has been implicated in the generation of
TR in the periphery (Fantini et al., 2004; Rao et al., 2005; Selvaraj and
Geiger, 2007; Yamazaki et al., 2007).
In our previous studies we identiﬁed a subpopulation of CMV-
speciﬁc T cells phenotypically deﬁned as CD4+CD27−CD28−, whose
frequency inversely correlated with in vitro CMV-speciﬁc proliferation
of peripheral blood mononuclear cells (PBMC) and positively
correlated with CMV-stimulated TGFβ production (Jesser et al.,
2006). In this study, we show that CD4+CD27−CD28− T cells puriﬁed
from CMV-stimulated PBMC inhibit de novo proliferation of autolo-
gous PBMC in response to CMV antigenic stimulation, fulﬁlling the
Fig. 1. CMV-speciﬁc CD4+CD27−CD28− T cells inhibit CMV-stimulated proliferation of autologous PBMC. A: Gating strategy for CD4+CD27−CD28− separation. CMV-stimulated
PBMC were stained using the following conjugated mAbs: anti-CD3-AmCyan, anti-CD4-PE Texas Red, anti-CD27-FITC and anti-CD28-FITC surface markers. Cells in the lymphocyte
gate delineated by side and forward scatter (left plot) were analyzed for expression of CD3 and CD4 (middle plot) and subsequently combined CD27 and CD28 (right plot). Using a cell
sorter, CD4+CD27−CD28− cells were separated from CD4+nonCD27−CD28− cells. B: Data were derived from 6 experiments using PBMC from independent donors. Freshly thawed
autologous PBMC were treated with CMV-speciﬁc CD4+CD27−CD28− cells at the indicated ratios and stimulated with CMV lysate for 6 days. Percent inhibition of CMV-stimulated
proliferation was calculated by the following formula: (1−median cpm in treated wells/median cpm in untreated wells)⁎100. Bars represent means and SEM. The inhibition of
proliferation was dose-dependent as shown by linear trend analysis (p value and r2 depicted in the graph). C: Freshly thawed PBMC from 3 donors were treated with autologous
CMV-speciﬁc CD4+nonCD27−CD28− cells prior to de novo CMV stimulation. Ratios were similar to the experiments depicted in panel B. Untreated indicates no added cells. Bars
represent means and SEM of median cpm for each condition. There was no evidence of a CD4+nonCD27−CD28− inhibitory effect on proliferation of autologous PBMC.
Fig. 2. Comparison of the inhibitory effect of CMV-speciﬁc CD4+CD27−CD28− TR with
that of CD4+CD25+CD127− natural TR on CMV-stimulated proliferation of autologous
PBMC. Light bars represent mean and SEM of 9 experiments that measured the
inhibitory effect of CMV-speciﬁc CD4+CD27−CD28− TR at the indicated ratios. Dark
bars represent mean and SEM of 3 experiments that measured the effect of CD4+CD25+
CD127− natural TR on CMV-speciﬁc proliferation. The 2-way ANOVA analysis did not
reveal any appreciable differences.
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effector mechanism characteristics of the CMV-stimulated CD4+
CD27−CD28− TR.
Results
Anti-proliferative effect of CMV-stimulated CD4+CD27−CD28− TR
To assess the TR activity of CMV-stimulated CD4+CD27−CD28− T
cells, PBMC from 6 CMV-seropositive healthy donors were stimulated
in vitro for 6 days with CMV lysate, after which CD4+CD27−CD28−
cells were isolated by ﬂow cytometry (Fig. 1A). The CMV-stimulated
CD4+CD27−CD28− T cells or CD4+non-CD27−CD28− controls were
added to 100,000 freshly thawed autologous PBMC in quadruplicate
wells at 1:3, 1:10 and 1:30 ratios and allowed to expand for 6 days in
the presence of CMV antigen. Proliferation was compared with that
of untreated PBMC cultures. The addition of CMV-stimulated CD4+
CD27−CD28− cells decreasedCMV-speciﬁc proliferation of autologous
PBMC in a dose-dependent fashion from mean±SEM 86±5% at a TR:
PBMC ratio of 1:3 to 25±12% at a ratio of 1:30 (r2=0.61, p=0.0001,
ANOVA for repeated measures; Fig. 1B). In contrast, the addition of
CD4+non-CD27−CD28− T cells, which included CD4+CD27+CD28+,
CD4+CD27+CD28− and CD4+CD27−CD28+ cells, tended to increase
CMV-induced proliferation of the autologous PBMC (Fig. 1C). These
data indicated that downregulation of CMV-stimulated PBMC prolif-
eration was a speciﬁc effect of the CD4+CD27−CD28− T cells.
Next, we compared the anti-proliferative effect of sorted CMV-
stimulated CD4+CD27−CD28− TR obtained from 3 HIV-infectedindividuals (CD4 of 200 to 947 cells/μl plasma HIV RNA b400
copies/ml) with those from 6 healthy subjects by adding the TR to
their autologous PBMC at a 1:3 ratio in the presence of CMV lysate for
6 days. Inhibition of in vitro proliferation of PBMC by TR was similar in
HIV-infected and uninfected subjects (87±3% vs. 85±5%), indicating
that the function of CMV-stimulated CD4+CD27−CD28− did not
Fig. 3. Frequency of CD4+CD27−CD28− TR in CMV-stimulated compared with mock-
infected control and C. albicans-stimulated PBMC. Data were derived from 10 CMV-
seropositive HIV-seropositive (CD4 of 200 to 957 cells/μl; plasma HIV RNAb400
copies/ml), 7 CMV-seropositive HIV-seronegative, and 4 CMV-seronegative HIV-
seronegative individuals. The enumeration of CD4+CD27−CD28− was performed
after 6 days of in vitro PBMC stimulation with the indicated antigens. CMV stimulation
signiﬁcantly increased the proportion of CD4+CD27−CD28− TR in CMV-seropositive
individuals, irrespective of their HIV status, but not in CMV-seronegative donors.
Candida stimulation moderately increased CD4+CD27−CD28− TR.
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Based on this observation, some of the subsequent analyses combined
data generated using cells from HIV-infected and uninfected indivi-
duals as described below.
To assess the relative TR potency of CMV-induced CD4+CD27−
CD28− T cells, we compared their inhibitory effect on proliferation
with that of CD4+CD25+CD127− natural TR. Natural TR selected by
ﬂow cytometry from freshly thawed PBMCwere added at ratios of 1:3,
1:10 and 1:30 to autologous PBMC, which were subsequently
stimulated with CMV lysate for 6 days. The data (Fig. 2) showed
that CMV-stimulated CD4+CD27−CD28− TR and freshly thawed
CD4+CD25+CD127− TR generated comparable inhibition of CMV-
speciﬁc proliferation when added to autologous PBMC (p=0.68, 2-
way ANOVA).Fig. 4. Antigen speciﬁcity of the anti-proliferative effect of CD4+CD27−CD28− TR. Data were
506 to 947 cells/μl; plasma HIV RNA b400 copies/ml) and 7 healthy subjects. Panel A show
stimulated CD4+CD27−CD28− TR at a ratio of 1:10. Panel B shows C. albicans-speciﬁc prolif
counts per minute (cpm). P values were calculated by paired t test of log10cpm. Panel C s
following formula: (1−median cpm in treated wells/median cpm in untreated wells)⁎10Speciﬁcity of the generation and of the effect of CMV-stimulated
CD4+CD27−CD28− TR
To determine if CD4+CD27−CD28− TR were speciﬁcally generated
as an adaptive response to antigenic stimulation, we compared the
frequencies of CD4+CD27−CD28− T cells in CMV and control antigen-
stimulated PBMC cultures obtained from 10 CMV-seropositive HIV-
infected, 7 CMV-seropositive HIV-seronegative and 4 CMV-seroneg-
ative HIV-seronegative subjects (Fig. 3). CMV stimulation generated a
signiﬁcantly higher frequency of CD4+CD27−CD28− TR compared
with mock-infected control stimulation in CMV-seropositive HIV-
seropositive and in CMV-seropositive HIV-seronegative individuals (p
of 0.003 and 0.009, respectively). In contrast, CMV-seronegative
individuals had equally low frequencies of CD4+CD27−CD28− cells in
CMV lysate- and mock-infected control-stimulated PBMC cultures,
and a trend towards higher CD4+CD27−CD28− TR in Candida
albicans-stimulated cell preparations (p=0.06). It is important to
note that the frequency of CD4+CD27−CD28− cells in control antigen-
stimulated cultures was signiﬁcantly lower in CMV-seronegative
compared with CMV-seropositive subjects (p=0.03) and that among
CMV-seropositive donors, the frequency of CMV-stimulated CD4+
CD27−CD28− TR was signiﬁcantly higher among cells from HIV-
seropositive compared with HIV-seronegative donors (p=0.01).
The speciﬁcity of the anti-proliferative effect of CMV-stimulated
CD4+CD27−CD28− TR was assessed by comparing their inhibitory
effect on proliferation of autologous PBMC stimulated with CMV vs. C.
albicans. CD4+CD27−CD28− TR generated in CMV-stimulated cultures
were added at a ratio of 1:10 to autologous PBMC, which were
subsequently stimulated with C. albicans antigen or CMV lysate for 6
days. The data generated with PBMC from 3 HIV-infected (median
CD4=322 cells/μl; median plasma HIV RNA b400 copies/ml) and 7
uninfected individuals showed no difference in inhibitory effect by
HIV status. Although both CMV- (Fig. 4A) and C. albicans-stimulated
(Fig. 4B) proliferation decreased after the addition of CD4+CD27−
CD28− TR (p of 0.002 and 0.02, respectively), the inhibitory effect of
the CD4+CD27−CD28− TR on CMV-speciﬁc proliferation was N3-fold
greater than their effect on C. albicans-stimulated proliferationderived from 10 experiments including PBMC from 3 HIV-infected individuals (CD4 of
s inhibition of CMV-speciﬁc proliferation of PBMC after addition of autologous CMV-
eration in similar experimental conditions. Incorporated radioactivity was measured in
hows percent inhibition of C. albicans- or CMV-stimulated PBMC calculated with the
0. Bars represent means and SEM. P values were obtained by paired t test analysis.
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t test; Fig. 4C).
Phenotypic characterization of CMV-stimulated CD4+CD27−CD28− TR
We assessed the expression of markers known to be overrepre-
sented in previously described natural and adaptive TR. The
expression of the markers of interest on CD4+CD27−CD28− TR was
compared with their expression on the parent CD4+ T-cell population
after 6 days of in vitro CMV stimulation (Fig. 5A). Compared with theFig. 5. Phenotypic characteristics of the CMV-speciﬁc CD4+CD27−CD28− TR. PBMCwere stim
shows an example of the gating strategy used to measure the expression of TGFβ on the
frequency of cells expressing TGFβ or other markers (not depicted) was measured in the
subpopulation (UL). Panel B shows markers over-expressed by the CD4+CD27−CD28− TR (1
by CD4+CD27−CD28− TR (5 and 20 samples for CD127 and PD1-L, respectively). Panel D sh
CD4+CD27−CD28− TR (6 to 17 samples/analyte).entire CMV-stimulated CD4+ T-cell population, a higher frequency of
CMV-stimulated CD4+CD27−CD28− TR expressed FoxP3 (p=0.02),
TGFβ (p=0.03), GITR (p=0.01), PD-1 (p=0.003), granzyme B
(p=0.0003), and perforin (p=0.05) (Fig. 5B). A signiﬁcantly lower
proportion of CMV-stimulated CD4+CD27−CD28− TR expressed
CD127 and PD-1L (pb0.0001 and 0.0005, respectively, Fig. 5C).
There were no appreciable differences in the frequencies of CD25+,
CTLA-4+, GITR-L+, or Fas-L+ cells (Fig. 5D).
The comparison of the phenotypic characteristics of CMV-
stimulated CD4+CD27−CD28− from HIV-infected and uninfectedulated in vitrowith CMV lysate for 6 days and stained for the indicated markers. Panel A
CD4+ populations of interest. PBMC were stimulated for 6 days with CMV lysate. The
total CD4+ cell population (UL+UR) and in the individualized CD4+CD27−CD28−
3 to 23 independent samples for each marker). Panel C shows markers under-expressed
ows markers whose expression was not appreciably different between CD4+ cells and
Table 1
Comparative expression of selective phenotypic markers by CMV-speciﬁc CD4+CD27−
CD28− TR from HIV-infected and uninfected donors.
Marker HIV-infected HIV-uninfected pa
FoxP3 37.7±9b (Nc=6) 29.2±10.7 (N=7) 0.56
TGFβ 24.0±10.3 (N=10) 22.8±8.0 (N=10) 0.93
Granzyme B 38.5±9.9 (N=11) 41.9±8.5 (N=12) 0.79
PD-1 50.3±12.9 (N=10) 30.4±9.3 (N=5) 0.33
PD1-L 41.2±14.3 (N=10) 32.9±8.4 (N=5) 0.58
a Calculated by t test.
b Numbers represent percent CD4+CD27−CD28− cells expressing the indicated
marker.
c N indicates the number of donors.
162 A. Tovar-Salazar et al. / Virology 398 (2010) 158–167individuals studied in parallel did not reveal appreciable differences
(Table 1). The data showed that the CMV-stimulated CD4+CD27−
CD28− TR of HIV-infected and uninfected individuals did not
appreciably differ with respect to the frequency of cells expressing
FoxP3, TGFβ, granzyme B, PD-1 or PD1-L.
To determine if the increased expression of FoxP3, TGFβ, granzyme
B and PD-1 occurred on a single unique subpopulation of the CMV-
speciﬁc CD4+CD27−CD28− cells as opposed to each marker being
expressed by distinct subpopulations, further phenotypic character-
ization was performed on PBMC from 8 subjects using polychromatic
ﬂow cytometry (Fig. 6A). The frequency of TGFβ-expressing cells wasFig. 6. Co-expression of FoxP3, TGFβ, granzyme B and PD-1 on CMV-speciﬁc CD4+CD27−CD
stained for the indicated markers. Panel A shows examples of the gating strategy. In the up
(middle plot). Next, we measured the frequency of cells expressing granzyme B among th
lower left and right areas, a similar strategy is depicted for measuring expression of TGFβ on
cells, respectively. The bar graphs represent means and SEM of the 8 experiments and show
compared with CD4+CD27−CD28−FoxP3− cells (B); CMV-speciﬁc CD4+CD27−CD28−TGFβ+
with CD4+CD27−CD28−TGFβ− cells.higher in CD4+CD27−CD28−FoxP3+ cells compared with CD4+
CD27−CD28−FoxP3− cells (66.1±12.4% vs. 29.8±7.9%; p=0.003;
Fig. 6B). Likewise, compared with CD4+CD27−CD28−TGFβ− cells, a
higher proportion of CD4+CD27−CD28−TGFβ+ cells expressed FoxP3
(36.2±9.2% vs. 7.2±2.7%; p=0.006; Fig. 6C); granzyme B (71.0±
7.3% vs. 35.2±3.8%; p=0.0003; Fig. 6D); and PD-1 (40.0±3.5% vs.
15.3±3.3%; pb0.0001; Fig. 6E). Taken together, these data supported
the co-expression of FoxP3, TGFβ, granzyme B and PD-1 by a unique
subpopulation of CD4+CD27−CD28− T cells.
Growth characteristics of CMV-speciﬁc CD4+CD27−CD28− TR
To identify the growth restrictions of CMV-speciﬁc CD4+CD27−
CD28− TR, we compared the proliferation of the CMV-stimulated
CD4+CD27−CD28− TR with that of CD4+nonCD27−CD28− lympho-
cytes in response to CMV lysate, mock-infected control or IL2
stimulation. CD4+CD27−CD28− and CD4+nonCD27−CD28− cells
were sorted from CMV-stimulated PBMC using the gating strategy
depicted in Fig. 1A, washed and allowed to expand for 6 days in the
presence of CMV lysate, mock-infected control antigen or IL2.
Comparedwithmock-infected control antigen stimulation conditions,
the CMV-speciﬁc CD4+CD27−CD28− TR proliferated in response to IL-
2 (p=0.02; Fig. 7A), but not in response to CMV lysate (p=0.33;
N=4; Fig. 7A). In parallel experiments, the CMV-stimulated CD4+
nonCD27−CD28− T cells proliferated in response to IL-2 (p=0.002;28− TR. PBMC from 8 donors were stimulated in vitro with CMV lysate for 6 days and
per group, gated CD4+CD27−CD28− TR (left plot) were analyzed for TGFβ expression
e CD4+CD27−CD28−TGFβ− and the CD4+CD27−CD28−TGFβ+ subpopulations. In the
granzyme B+ compared with granzyme B− cells and on PD-1+ compared with PD-1−
that a higher proportion of CMV-speciﬁc CD4+CD27−CD28−FoxP3+ cells express TGFβ
cells express FoxP3 (C), granzyme B (D) and PD-1(E) in a higher proportion compared
Fig. 6 (continued).
163A. Tovar-Salazar et al. / Virology 398 (2010) 158–167Fig. 7B) and in response to CMV lysate (p=0.02; Fig. 7B). Taken
together, these data indicate that both IL2 and CMV lysate stimulation
are able to generate expansion of a mixed CD4+ subpopulation.Fig. 7. Growth characteristics of CMV-speciﬁc CD4+CD27−CD28− TR. Sorted CMV-
speciﬁc CD4+CD27−CD28− (A) and CD4+nonCD27−CD28− (B) were restimulated for
6 days with mock-infected control antigen (mock), CMV lysate (CMV) or IL2. Data
points represent 3H-thymidine incorporation (cpm) measured at the end of the
restimulation period. P values were calculated by paired t test of log10cpm.However, the CMV-speciﬁc TR lose their ability to expand in response
to CMV stimulation while retaining responses to IL2.
Mediators of the regulatory effect of CMV-stimulated CD4+CD27−
CD28− TR
The phenotypic characterization of the CMV-stimulated CD4+
CD27−CD28− TR suggested several potential candidates as media-
tors of their anti-proliferative effect, including TGFβ, granzyme B and
PD-1. In order to investigate the role of these putative mediators,
CMV-stimulated CD4+CD27−CD28− TR were treated with neutraliz-
ing mAbs anti-TGFβ or anti-PD-1 or with a granzyme B inhibitor with
combined intra- and extra-cellular activity. The anti-proliferative
activity of the treated TR was compared with that of untreated TR in
paired experiments by adding them to autologous PBMC at a 1:10
ratio and allowing the cell culture to proliferate in the presence of
CMV lysate for 6 days. All 3 blocking agents partially reversed the anti-
proliferative effect of the TR from 72±8 to 51±9% for anti-TGFβ
(N=7; p=0.04; Fig. 8A); from 69±9% to 59±11% for anti-PD-1
(N=6; p=0.05; Fig. 8B); and from 75±9% to 38±14% for the
granzyme B inhibitor (N=7; p=0.02; Fig. 8C). Parallel experiments
inwhich CMV-stimulated CD4+CD27−CD28− TRwere treatedwith an
irrelevant mouse IgG2b mAb prior to incubation with autologous
PBMC, showed no appreciable change in the anti-proliferative effect of
the TR (N=4; p=0.77; Fig. 8D). Overall, inhibition of granzyme B
activity had the most robust downregulatory effect on the anti-
proliferative activity of the CD4+CD27−CD28− TR. There was no
synergistic activity of granzyme B, TGFβ and PD-1 inhibitors (data not
shown).
Discussion
We demonstrated the TR activity of CMV-stimulated CD4+CD27−
CD28− T cells from CMV-seropositive donors. CMV infection is known
to increase the frequency of circulating CD4+CD27−CD28− T cells
(Bekker et al., 2005; Bronke et al., 2007; Hooper et al., 1999; van
Leeuwen et al., 2004). Because these cells express granzyme B in
abundance, it was postulated that they represented cytotoxic effectors
whose targets were CMV-infected cells (Casazza et al., 2006; van
Fig. 8. Mediators of the anti-proliferative effect of CMV-speciﬁc CD4+CD27−CD28− TR. CD4+CD27−CD28− TR sorted from CMV-stimulated PBMC were treated with anti-TGFβ
neutralizing mouse mAbs (A), anti-PD-1 blocking mouse mAbs (B), granzyme B inhibitors (C) or an irrelevant control mouse mAb (D) before incubation with autologous PBMC. The
bars represent inhibition of CMV-stimulated proliferation of PBMC incubated with treated or untreated TR in paired experiments.
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CD27−CD28− cells from CMV-seropositive donors inhibit CMV-
speciﬁc proliferation of autologous PBMC and exhibit other TR
characteristics, such as expression of FoxP3, GITR and TGFβ and not
of CD127; lack of growth in response to antigenic restimulation, but
signiﬁcant expansion in the presence of IL2. Further studies are
needed to determine if the CD4+CD27−CD28− TR are generated as TR
or evolve from effector cells who acquire different functions over the
course of the CMV infection in a similar fashion to the process
described in mice infected with lymphocytic choriomeningitis virus
(Brooks et al., 2006; Knoechel et al., 2005).
We explored the mechanism used by the CD4+CD27−CD28− TR to
inhibit proliferation of autologous PBMC using blocking experiments.
Treatment of the CMV-speciﬁc CD4+CD27−CD28− TR with anti-TGFβ
neutralizing antibodies reduced the anti-proliferative effect of the TR
by 30%. This effect was consistent both with the anti-proliferative
effect of TGFβ on Th1 lymphocytes and with the TR-inducing activity
of TGFβ (Broderick and Bankert, 2006; Classen et al., 2007; Rao et al.,
2005; Rubtsov and Rudensky, 2007). These two effects of TGFβ are not
mutually exclusive and both may operate simultaneously.
Inhibition of granzyme B, which is expressed by a high proportion
of the CD4+CD27−CD28− TR, reduced the CMV-speciﬁc anti-prolifer-
ative effect of the CD4+CD27−CD28− TR by 50%. Granzyme B is a
traditional mediator of cytotoxicity that can act alone or in concert
with perforin. We also showed that perforin was expressed by a
higher proportion of CMV-stimulated CD4+CD27−CD28− lympho-
cytes compared with their parent CD4+ T-cell population. Both
granzyme B and perforin have been shown to play a critical role in
terminating acute immune responses (Gondek et al., 2005; Grossman
et al., 2004; Voskoboinik et al., 2006). Granzyme B and other
granzymes induce apoptosis of the target cells, which is a common
mechanism used by the immune system to regulate its responses
(Mateo et al., 2007; Pardo et al., 2004).
PD-1 upregulation has been commonly described in association
with TR, although some studies found it expressed on the surface of TRand others found it sequestered in the cytoplasm (Chemnitz et al.,
2007; Raimondi et al., 2006; Sandner et al., 2005). Blocking PD-1 on
the CD4+CD27−CD28− TR with anti-PD-1 neutralizing mAbs was
associated with a 10% reduction of the TR anti-proliferative effect.
Although statistically signiﬁcant, the effect of blocking PD-1 was small
and, therefore, its biological signiﬁcance remains questionable.
The increased frequency of circulating CD27− and CD28− T cells
is one of the characteristics of CMV infection (Bekker et al., 2005;
Pourgheysari et al., 2007; van de Berg et al., 2008; Yue et al., 2004).
Based on their in vitro TR activity, we propose that these cells may
play a role in the immunosuppression associated with CMV
infection. Other investigators described a negative association
between the frequency of CD27− and/or CD28− circulating T cells
and the immune repertoire of CMV-seropositive hosts (Almanzar et
al., 2005; Sylwester et al., 2005; Vescovini et al., 2007). It was also
previously shown that CMV-speciﬁc T cells suppress responses to
other viruses in young and elderly individuals (Khan et al., 2004;
Levin et al., 1979) and it was proposed that this phenomenon may
contribute to the association between CMV seropositivity and
increased risk of death in octogenarians and nonagenarians
(Wikby et al., 2005). The immunosuppressive effect of CMV infection
has been well documented in transplant patients who become more
susceptible to bacterial and fungal super-infections during CMV
reactivations. In HIV-infected patients, CMV reactivation is associat-
ed with increased risk of death independent of the development of
CMV end-organ disease (Deayton et al., 2004; Wohl et al., 2005). We
also showed that CMV stimulation of PBMC from HIV-infected
subjects elicits higher frequencies of CD4+CD27−CD28− TR than in
HIV-seronegative individuals (Jesser et al., 2006). It is conceivable
that the CMV-stimulated CD4+CD27−CD28− TR may attenuate
immune responses to other pathogens through a nonspeciﬁc effect
similar to the one that we described against C. albicans antigen-
induced proliferation. The role of CD4+CD27−CD28− as mediators of
the immune suppression associated with CMV infection deserves to
be further investigated.
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Subjects
PBMC used in this study were obtained from 15 HIV-infected and
23 uninfected subjects. All subjects were CMV-seropositive. Inclusion
criteria for HIV-infected individuals included HAART treatment ≥3
months (3-drug regimen, including at least one protease inhibitor or a
non-nucleoside analogue) and CD4+ counts ≥100 cells/μl at study
entry. At study visits for immunologic evaluations, the median CD4+
numbers of HIV-infected subjects was 506 cells/μl (range of 200 to
947 cells/μl). HIV viral load was b400 copies/ml. The median time on
HAART was 20 months.
Monoclonal antibodies (MAb) and other reagents
The following staining reagents were used in this study: anti-CD3-
AmCyan, anti-CD27-FITC, anti-CD28-FITC and anti-CTLA-4-APC (BD
Biosciences); anti-CD4-PE Texas Red, anti-granzyme B-PE-Cy5.5, anti-
CD25-APC and anti-Fas-L-APC (Caltag); anti-TGF-β-biotin, streptavi-
din-PE-Cy7, anti-FoxP3-APC, anti-PD1-L, anti-PD-1-PE, anti-GITR-L-
Alexa647, anti-GITR-PerCP and streptavidin-APC (eBiosciences); goat
anti-mouse IgG-Paciﬁc Blue, goat anti-mouse IgG-Alexa Fluor 750-
APC and anti-GPR83-APC (Invitrogen); anti-TGF-β-PE (IQ Products);
and anti-perforin-biotin (Ancell). The following blocking reagents
were used in this study: anti-TGF-β1 and anti-human PD-1 mouse
mAb's (R&D Systems, Inc), granzyme B inhibitor II, cell-permeable
(Calbiochem).
Specimen processing and cryopreservation
PBMC from heparinized blood, separated by Ficoll-Hypaque
density gradient centrifugation (Sigma Chemical Company), were
cryopreserved at 107 cells/ml in fetal bovine serum (FBS, Gemini Bio-
Products) with 10% dimethyl sulfoxide (DMSO, Sigma Chemical
Company) and stored in liquid nitrogen tanks until use.
Lymphocyte proliferation assay (LPA)
PBMC at 106 cells/ml in stimulation medium consisting of RPMI
1640 with L-glutamine (Gibco), 10% human AB serum (GemCell) and
1% penicillin–streptomycin (Gibco) were incubated in quadruplicate
wells of 96-well microtiter plates at 100 μl/well with 100 μl of
inactivated CMV-infected cell lysate, mock-infected cell control
antigen, recombinant human IL-2 at 4 ng/ml (R&D Systems, Inc), C.
albicans antigen (Greer), or phytohemagglutinin (Sigma). After 6 days
of culture at 37 °C in 5% CO2 atmosphere, cells were pulsed with 1 μCi
of 3H-thymidine and their DNA was harvested 6 h later onto Uniﬁlter
plates (Perkin Elmer). Radioactivity gathered on the ﬁlters was
counted with a microplate scintillation counter (Packard) and
scintillation ﬂuid (Perkin Elmer). Results were expressed in median
counts per minutes (cpm) of the quadruplicate wells.
T-cell phenotypic characterization
PBMC and separated T-cell subpopulations were allowed to
expand in culture tubes containing stimulation medium with CMV
lysate, C. albicans or control antigen for 6 days at 37 °C in 5% CO2
atmosphere, after which cells were washed twice in 2% FBS in PBS and
incubated for 30 min at room temperature with the surface marker
mAbs described above. For intracellular staining, PBMC were then
permeabilized and ﬁxed (Cytoﬁx/Cytoperm; BD Pharmingen) for 20
min at 4 °C, washed and incubated with the appropriate mAbs. At the
completion of the staining procedure, PBMCwere washed in 2% FBS in
PBS and analyzed with a FACSCalibur using CellQuest software or
FACSAria using FACSDiva software (BD Biosciences), or FlowJo(Treestar). The gating strategy took into account the distribution of
cells with respect to the markers of interest and the ﬂuorescence
minus one histograms.
Cell sorting
After 6 days of CMV stimulation at 37 °C in 5% CO2 atmosphere,
PBMC were washed twice in 2% FBS in PBS and stained for surface
markers as described above. After that, cells were washed in 2% FBS in
PBS and sorted using FACSAria using FACSDiva software (BD
Bioscience) or MoFlo™ XDP (Dako) using Summit software. Sorted
PBMC were collected in stimulation medium and used in functional
experiments.
Blocking experiments
Puriﬁed CD4+CD27−CD28− cells were treated with granzyme B
inhibitor II (Calbiochem), neutralizingmAbs anti-TGFβ (R&D Systems,
Inc) or anti-PD1 (R&D Systems, Inc), or an irrelevant mouse mAb
control (BD Bioscience) for 2 h at 37 °C in 5% CO2 atmosphere in
stimulation medium. Treated and untreated CD4+CD27−CD28− cells
were added to freshly thawed autologous PBMC in the presence of
inactivated CMV-infected cell lysate. After 6 days of incubation in
quadruplicate 96-microtiter plate wells/stimulant, cells were pulsed
with 3H-thymidine, harvested and counted as above.
Statistical analysis
Statistical analysis was performed using Prism 4 (GraphPad). Two-
tailed t tests were used for the analyses in which a p value≤0.05 was
considered signiﬁcant. Distribution of results was checked for
normality and parametric tests were applied to normally distributed
data. Log transformation was applied when indicated to achieve
normal distribution of the data.
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